Tirzepatide Good price
2048 Inquiries
2023788-19-2
10mg*10vials
2026-05-31
Peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
Basic Info-
Product Name:
Tirzepatide
Other Name:LY3298176;
CAS No.:2023788-19-2
Molecular Formula:C225H348N48O68
Molecular Weight:4813
EC Number:200-001-8
Categories:
Characteristics-
Appearance:
White to off-white
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptide
-
Location:
3rd Floor, Room 323, Building 3, No. 87 West Jiancai Road, Changping District, Beijing
-
Year of Establishment:
2024
-
-
Inquiry History2048 Inquiries
Country Product Purchase Quantity Date Posted 
United States
2023788-19-2 in unlabeled vials 10, 15 and 30 mg
10 Feb 14, 2024
United States
Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss 399 Inquiries
10 MG Apr 3, 2024
United States
Tirzepatide Raw Powder Weight Loss Peptides CAS No 2023788-19-2 Tirzepatide Injection Peptides
2 MT Dec 13, 2025 
Hongkong, China
2023788-19-2
1 KG Aug 13, 2026 
Germany
2023788-19-2
1 MG Jun 18, 2026
United States
2023788-19-2 Retatrutide
1 G Sep 22, 2023
United States
2023788-19-2 Trizepatide
10 MT Oct 29, 2023
United States
Tirzepatide 2023788-19-2
2 Feb 19, 2024
United States
Tirzepatide 2023788-19-2
10 G Oct 31, 2023
United States
Trizepatide 2023788-19-2 Raw Material LY3298176 Tirzepatide powder
1 Dec 2, 2025
United States
Fat Burning Peptides Tirzepatide 10mg/Vial 15mg/Vial Tirzepatide CAS: 2023788-19-2
1 MT Jan 25, 2024
United States
Pharmacy Grade CAS 2023788-19-2 Tirzepatide 99% White powder Tirzepatide
1 MT Oct 20, 2023
United States
Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss
2 KG Oct 20, 2023
United States
supply Tirzepatide Safe Material Shipping Trizepatide 2023788-19-2 Raw Tirzepatide powder
10 MG Apr 4, 2024
United States
COA Offer Top quality Weight Loss Peptides Tirzepatide 10mg/vial GLP-1 2023788-19-2
1 MT Sep 10, 2023 
Kenya
Janoshik Test Tirzepatide 99% White powder High Quality Tirzepatide Weight loss CAS 2023788-19-2
30 MG Dec 26, 2025
United States
Ex-factory price tirzepatide T30 10vials 30mg kit cas 2023788-19-2 for weight loss peptide
10 Dec 30, 2024 
United Kingdom
Manufacturer supply high quality hot sale lowest price Tirzepatide CAS NO,2023788-19-2 99% powder 2023788-19-2 Claire
100 G Nov 4, 2023 
Canada
99.9% Purity GLP-1 Injection Weight Loss Peptides Liraglutide Retatrutide Tirzepatide Semaglutide 5mg 10mg CAS 2023788-19-2
2 MT Oct 22, 2023
United Kingdom
tirzepatide
10 MG Oct 21, 2025 Post an enquiry for this product